Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Three New Biopharma IPOs In The US With Eight More Entering The Queue

Executive Summary

Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.


Related Content

IPO Update: Pace Of US Offerings Slows As 13 Biopharmas Go Public In 2019
Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties
BridgeBio’s $299m Gives It Two More Years Of Runway To Launch New Companies
Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom
Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Finance Watch: Investors Can't Get Enough Of NASH, Including Start-Ups With Novel Drugs
Darzalex Excites As Potential Grows In Multiple Myeloma
Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate
Arikayce’s Limited Population, Black Box Warning Won’t Limit Launch, Insmed Says
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts